Vertex Pharmaceuticals Inc

Research Vertex Pharmaceuticals Inc (VRTX) on Bullrun: valuation model: 8.8% overvalued, market cap USD 129.23B, P/E 29.7. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

Bullrun's latest valuation model marks Vertex Pharmaceuticals Inc as 8.8% overvalued; latest market cap is USD 129.23B; P/E is 29.7.

Peer valuation comparison

Latest P/E is 29.68x versus a Healthcare sector median of 24.64x (20.4% above).

Latest P/E is 29.68x versus a United States median of 23.85x (24.4% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 12.00BUSD 3.95BUSD 3.19B86.2%15.32USD 5.08BUSD 2.03BUSD 18.67B
FY2024USD 11.02B-USD 535.60M-USD 790.30M86.1%-2.08USD 4.57BUSD 1.74BUSD 16.41B
FY2023USD 9.87BUSD 3.62BUSD 3.34B87.2%13.89USD 10.37BUSD 808.40MUSD 17.58B
FY2022USD 8.93BUSD 3.32BUSD 3.93B87.9%12.82USD 10.50BUSD 899.70MUSD 13.91B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-09USD 129.23B29.7n/an/a
20252025-12-31USD 115.15B29.6n/an/a
20242024-12-31USD 103.47Bn/an/an/a
20232023-12-29USD 104.85B30.5n/an/a
20222022-12-30USD 74.13B22.8n/an/a
20212021-12-31USD 55.88B24.3n/an/a

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older;

ETFs that hold Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc is one of the ten largest holdings of 14 ETFs that investors in Europe can buy. The 8 most traded of them:

ETFWeightTER
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)8.13%0.35%
Global X Genomics & Biotechnology UCITS ETF USD Acc3.72%0.50%
L&G Healthcare Technology & Innovation ETF USD Acc2.05%0.49%
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)7.67%0.35%
VanEck Genomics and Healthcare Innovators UCITS ETF7.53%0.35%
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C USD Acc4.33%0.30%
UBS Factor MSCI World Selection Minimum Volatility UCITS ETF USD acc1.46%0.25%
First Trust Capital Strength UCITS ETF Class A USD Accumulation2.22%0.60%

Compare every fund on the same index:

MSCI World Minimum Volatility ETFs

Related stock research

United States stocks United States Healthcare stocks A-Z stock index

Other Healthcare stocks

Aardvark Therapeutics Inc (AARD) Abeona Therapeutics Inc (ABEO) Acumen Pharmaceuticals Inc (ABOS) Absci Corp (ABSI) Arbutus Biopharma Corp (ABUS) ABVC BioPharma Inc (ABVC) Acadia Pharmaceuticals Inc (ACAD) Adicet Bio Inc (ACET) Achieve Life Sciences Inc (ACHV) Alpha Cognition Inc (ACOG) Aclaris Therapeutics Inc (ACRS) Acrivon Therapeutics Inc (ACRV)

Frequently asked questions

Is Vertex Pharmaceuticals Inc overvalued or undervalued?

Bullrun's valuation model currently marks Vertex Pharmaceuticals Inc as 8.8% overvalued.

What is Vertex Pharmaceuticals Inc's market cap?

Vertex Pharmaceuticals Inc's market capitalization is USD 129.23B.

What is Vertex Pharmaceuticals Inc's P/E ratio?

Vertex Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 29.7.

What does Vertex Pharmaceuticals Inc do?

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.